These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21494621)

  • 1. Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.
    Cerchietti L; Damm-Welk C; Vater I; Klapper W; Harder L; Pott C; Yang SN; Reiter A; Siebert R; Melnick A; Woessmann W
    PLoS One; 2011 Apr; 6(4):e18436. PubMed ID: 21494621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
    Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
    Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.
    Galkin AV; Melnick JS; Kim S; Hood TL; Li N; Li L; Xia G; Steensma R; Chopiuk G; Jiang J; Wan Y; Ding P; Liu Y; Sun F; Schultz PG; Gray NS; Warmuth M
    Proc Natl Acad Sci U S A; 2007 Jan; 104(1):270-5. PubMed ID: 17185414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases.
    Gascoyne RD; Lamant L; Martin-Subero JI; Lestou VS; Harris NL; Müller-Hermelink HK; Seymour JF; Campbell LJ; Horsman DE; Auvigne I; Espinos E; Siebert R; Delsol G
    Blood; 2003 Oct; 102(7):2568-73. PubMed ID: 12763927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma.
    Takeuchi K; Soda M; Togashi Y; Ota Y; Sekiguchi Y; Hatano S; Asaka R; Noguchi M; Mano H
    Haematologica; 2011 Mar; 96(3):464-7. PubMed ID: 21134980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
    Werner MT; Zhao C; Zhang Q; Wasik MA
    Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer.
    Takezawa K; Okamoto I; Nishio K; Jänne PA; Nakagawa K
    Clin Cancer Res; 2011 Apr; 17(8):2140-8. PubMed ID: 21415216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells.
    Tanizaki J; Okamoto I; Takezawa K; Sakai K; Azuma K; Kuwata K; Yamaguchi H; Hatashita E; Nishio K; Janne PA; Nakagawa K
    Br J Cancer; 2012 Feb; 106(4):763-7. PubMed ID: 22240786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion.
    Momose S; Tamaru J; Kishi H; Mikata I; Mori M; Toyozumi Y; Itoyama S
    Hum Pathol; 2009 Jan; 40(1):75-82. PubMed ID: 18755494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
    Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALK-positive diffuse large B-cell lymphoma of the stomach associated with a clathrin-ALK rearrangement.
    McManus DT; Catherwood MA; Carey PD; Cuthbert RJ; Alexander HD
    Hum Pathol; 2004 Oct; 35(10):1285-8. PubMed ID: 15492998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
    Mori M; Ueno Y; Konagai S; Fushiki H; Shimada I; Kondoh Y; Saito R; Mori K; Shindou N; Soga T; Sakagami H; Furutani T; Doihara H; Kudoh M; Kuromitsu S
    Mol Cancer Ther; 2014 Feb; 13(2):329-40. PubMed ID: 24419060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review.
    Rudzki Z; Rucińska M; Jurczak W; Skotnicki AB; Maramorosz-Kurianowicz M; Mruk A; Piróg K; Utych G; Bodzioch P; Srebro-Stariczyk M; Włodarska I; Stachura J
    Pol J Pathol; 2005; 56(1):37-45. PubMed ID: 15921012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene.
    Chen Z; Sasaki T; Tan X; Carretero J; Shimamura T; Li D; Xu C; Wang Y; Adelmant GO; Capelletti M; Lee HJ; Rodig SJ; Borgman C; Park SI; Kim HR; Padera R; Marto JA; Gray NS; Kung AL; Shapiro GI; Jänne PA; Wong KK
    Cancer Res; 2010 Dec; 70(23):9827-36. PubMed ID: 20952506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma.
    Mitou G; Frentzel J; Desquesnes A; Le Gonidec S; AlSaati T; Beau I; Lamant L; Meggetto F; Espinos E; Codogno P; Brousset P; Giuriato S
    Oncotarget; 2015 Oct; 6(30):30149-64. PubMed ID: 26338968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALK+, CD30-, CD20- large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC).
    Chikatsu N; Kojima H; Suzukawa K; Shinagawa A; Nagasawa T; Ozawa H; Yamashita Y; Mori N
    Mod Pathol; 2003 Aug; 16(8):828-32. PubMed ID: 12920229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
    Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
    J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.
    Heuckmann JM; Balke-Want H; Malchers F; Peifer M; Sos ML; Koker M; Meder L; Lovly CM; Heukamp LC; Pao W; Küppers R; Thomas RK
    Clin Cancer Res; 2012 Sep; 18(17):4682-90. PubMed ID: 22912387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma.
    De Paepe P; Baens M; van Krieken H; Verhasselt B; Stul M; Simons A; Poppe B; Laureys G; Brons P; Vandenberghe P; Speleman F; Praet M; De Wolf-Peeters C; Marynen P; Wlodarska I
    Blood; 2003 Oct; 102(7):2638-41. PubMed ID: 12750159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like).
    Touriol C; Greenland C; Lamant L; Pulford K; Bernard F; Rousset T; Mason DY; Delsol G
    Blood; 2000 May; 95(10):3204-7. PubMed ID: 10807789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.